港股異動丨再鼎醫藥盤前升近12% HER2靶向療法獲批上市 小摩增持公司H股
再鼎醫藥(ZLAB.US)美股盤前升11.84%,報29.19美元。H股今日收升超5%。消息面上,再鼎醫藥申報的馬吉妥昔單抗注射液已在中國獲批上市,本次獲批的適應症為用於轉移性HER2陽性乳腺癌患者三線及以上治療。此外,港交所資料顯示,小摩於8月29日增持再鼎醫藥H股98.3479萬股,總金額約為1783.15萬港元;增持後最新持股數目約1.29億股,持股比例為13.01%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.